A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*

Christine I. Chen, Harminder Paul, Lisa W. Le, Ellen N. Wei, Susi Snitzler, Trina Wang, Olga Levina, Sumeet Kakar, Anthea Lau, Michelle Queau, James B. Johnston, Deborah A. Smith, Suzanne Trudel
  • Leukemia & Lymphoma, June 2018, Taylor & Francis
  • DOI: 10.1080/10428194.2018.1468892
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Harminder Paul and Anthea Lau